COMP <GO>
VCEL vs ADMA // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Vericel Corporation (NASDAQ) VS. ADMA Biologics Inc (NASDAQ) • 15-METRIC TALLY: VCEL 3
— ADMA 9
■ METRIC PARITY
LAST: $42.91 (+4.43%) • MKT CAP: $2.20B
options-implied-move
—
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCEL VS. ADMA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCEL | ADMA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.40% | 57.40% | +17.00 | VCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 32.90% | -29.50 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 61.4x | 12.4x | +49.00 | ADMA | /valuation <GO> |
| Free Cash Flow Yield | 1.13% | 1.06% | +0.07 | VCEL | /fcf-yield <GO> |
| Operating Margin | 4.00% | 37.50% | -33.50 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 28.80% | -22.80 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 19.60% | -3.10 | ADMA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.94 | 12.98 | -3.04 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VCEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.0 | 67.9 | -11.90 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 111.7x | 15.0x | +96.70 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.20B | $2.63B | -$434.5M | ADMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCEL REV | ADMA REV | VCEL GROSS % | ADMA GROSS % | VCEL FCF | ADMA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $276.3M | $510.2M | 74.4% | 57.4% | $24.7M | $27.8M |
| FY 2024 | $237.2M | $426.5M | 72.6% | 51.5% | -$5.8M | $110.4M |
| FY 2023 | $197.5M | $258.2M | — | — | $35.3M | $8.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCEL // BETA —
ADMA // BETA —